Biogen (BIIB) revenue breakdown
By product, Product revenue, net is the largest at 72% of fiscal 2025 revenue; Contract manufacturing, royalty and other revenue grew fastest, 10% a year over 9 years.
Revenue by product
Fiscal years, as Biogen reports them in its 10-K filings; fiscal 2025 total $9.9B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $9.8B | $10.4B | $10.9B | $11.4B | $10.7B | $8.8B | $8.0B | $7.2B | $7.2B | $7.1B | 72% |
| Revenue from anti-CD20 therapeutic programs | $1.3B | $1.6B | $2.0B | $2.3B | $2.0B | $1.7B | $1.7B | $1.7B | $1.7B | $1.9B | 19% |
| Contract manufacturing, royalty and other revenue | $316M | $360M | $586M | $708M | $775M | $476M | $485M | $899M | $653M | $733M | 7% |
| Alzheimer's collaboration revenue | — | — | — | — | — | — | — | — | $60M | $178M | 2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BIIB.
Open BIIB in InvestinglyQuestions
Where does Biogen make its money?
In fiscal 2025, by product: Product revenue, net $7.1B, Revenue from anti-CD20 therapeutic programs $1.9B, Contract manufacturing, royalty and other revenue $733M, Alzheimer's collaboration revenue $178M.
From Biogen's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.